CTI BioPharma Corp. (CTIC)
Jun 26, 2023 - CTIC was delisted (reason: acquired by Sobi)
9.09
0.00 (0.00%)
Inactive · Last trade price on Jun 23, 2023
CTI BioPharma Revenue
CTI BioPharma had revenue of $24.12M in the quarter ending March 31, 2023, with 950.81% growth. This brings the company's revenue in the last twelve months to $75.77M, up 3,201.48% year-over-year. In the year 2022, CTI BioPharma had annual revenue of $53.95M.
Revenue (ttm)
$75.77M
Revenue Growth
+3,201.48%
P/S Ratio
15.82
Revenue / Employee
$596,606
Employees
127
Market Cap
1.20B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 53.95M | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 3.35M | -22.95M | -87.28% |
Dec 31, 2018 | 26.29M | 1.14M | 4.55% |
Dec 31, 2017 | 25.15M | -32.26M | -56.20% |
Dec 31, 2016 | 57.41M | 41.29M | 256.20% |
Dec 31, 2015 | 16.12M | -43.96M | -73.17% |
Dec 31, 2014 | 60.08M | 25.40M | 73.24% |
Dec 31, 2013 | 34.68M | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 319.00K | 239.00K | 298.75% |
Dec 31, 2009 | 80.00K | -11.35M | -99.30% |
Dec 31, 2008 | 11.43M | 11.31M | 8,901.57% |
Dec 31, 2007 | 127.00K | 47.00K | 58.75% |
Dec 31, 2006 | 80.00K | -16.01M | -99.50% |
Dec 31, 2005 | 16.09M | -13.50M | -45.62% |
Dec 31, 2004 | 29.59M | 4.83M | 19.50% |
Dec 31, 2003 | 24.77M | 7.87M | 46.57% |
Dec 31, 2002 | 16.90M | 10.66M | 170.94% |
Dec 31, 2001 | 6.24M | 5.73M | 1,142.23% |
Dec 31, 2000 | 502.00K | - | - |
Dec 31, 1999 | 0 | - | - |
Dec 31, 1998 | 13.20M | 1.37M | 11.57% |
Dec 31, 1997 | 11.83M | 2.71M | 29.72% |
Dec 31, 1996 | 9.12M | 9.02M | 9,020.81% |
Dec 31, 1995 | 100.00K | - | - |
Dec 31, 1994 | 0 | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCTIC News
- 2 years ago - Sobi completes acquisition of CTI BioPharma Corp. - PRNewsWire
- 2 years ago - Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp. - PRNewsWire
- 2 years ago - CTI BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CTI BioPharma Corp. - CTIC - Business Wire
- 2 years ago - CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders - PRNewsWire
- 2 years ago - Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp. - PRNewsWire
- 2 years ago - Swedish drugmaker SOBI to acquire Seattle biotech giant CTI BioPharma for $1.7B - GeekWire
- 2 years ago - CTI BioPharma Soars After Agreeing $1.7 Billion Sale. Biotech Deals Keep Coming. - Barrons
- 2 years ago - CTI BioPharma soars on deal news, while Upstart and Rivian climb after earnings - Market Watch